Release date: 2014-01-21
The Scripps Research Institute of the United States has developed a “liquid biopsy†technique to check whether a patient is at high risk for a heart attack by examining whether there is a special marker in the blood called circulating endothelial cells (CECs). . Related papers were published in the latest issue of the British Physical Society (IOP) publication Biomedical.
Vascular endothelial cells line the arterial wall and are closely related to the course of a heart attack as they circulate in the blood. The researchers believe that these circulating endothelial cells will appear lesion plaques, tissue breaks and ulcers, causing arterial inflammation. These lesions can form vascular obstructions that prevent blood from circulating in the arteries and eventually lead to a heart attack.
The principle of predictive screening techniques is to use healthy controls to identify circulating endothelial cells (CECs) and to identify patients who have recently received treatment for a heart attack. To this end, the researchers developed a procedure called HD Loop Cell Endothelial (HD-CEC) assay to detect and characterize CEC features in blood samples from 79 patients. These patients have experienced a heart attack. They used two control controls as a comparison, including 25 healthy individuals and 7 patients with vascular disease treated. The test recognizes both the appearance and the response of circulating endothelial cells to specific antibodies, and the levels of circulating endothelial cells in humans after a heart attack are significantly elevated.
“After a heart attack, circulating endothelial cells can be reliably detected in the patient's body, but not in the healthy control group. The goal of the research paper is to establish evidence, and we have succeeded in doing this.†Responsible for the study Peter Kuhn, an associate professor at the Lipps Institute, said, "Compared to the healthy control group, our results are very clear. The next step is to evaluate the usefulness of this test in the early identification of heart attacks."
Researchers believe that this technology is now available for people who show signs but have not yet had a heart attack. There have been no predictive tests for heart disease before, and at least the accuracy of the prediction is unsatisfactory.
They also compared the test results to an already commercialized CellSearch check, which has been approved by the US Food and Drug Administration to examine the number of tumor cells in cancer patients. The HD-CEC test showed greater specificity for circulating endothelial cells because it used direct analysis to avoid bias in the concentration phase. “Our tests can efficiently analyze millions of cells and are more efficient, but make sure you analyze all the suspicious cells of the patient.â€
Source: China Science and Technology Network - Technology Daily
China Basket Stretcher,Emergency Basket Stretcher manufacturers, welcome Seperatable Basket Stretcher,Helicopter Rescue Basket Strectcher purchasers from worldwide to visit our site.
Basket Stretcher,Emergency Basket Stretcher,Seperatable Basket Stretcher,Helicopter Rescue Basket Strectcher
Medton Medical , https://www.medton.cn